乳房切除术后的放射治疗:一个ASTRO/ASCO/SSO临床实践指南
Rachel B Jimenez1, Yara Abdou2, Penny Anderson3
1Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. rbjimenez@mgb.org.
Annals of surgical oncology
|September 16, 2025
概括
乳腺切除术后的放射治疗 (PMRT) 建议用于大多数节点阳性乳腺癌患者和选择节点阴性病例. 这些基于证据的指导方针提供了最佳乳腺癌治疗的最新指示,体积,剂量和技术.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 乳腺癌治疗方法 乳腺癌治疗方法
背景情况:
- 乳腺切除术后的放射治疗 (PMRT) 涉及治疗乳腺癌切除术后的胸壁和区域淋巴结.
- 随着证据的不断变化,需要更新PMRT指示,技术和治疗参数的指导方针.
研究的目的:
- 为乳腺癌治疗中使用乳腺切除术后放射治疗 (PMRT) 提供基于证据的建议.
- 详细说明PMRT在前期外科设置和新辅助全身疗法后的指示.
- 为了指导适当的目标体积,剂量和PMRT的治疗技术.
主要方法:
- 来自ASTRO,ASCO和SSO的多学科工作组召开会议,以解决PMRT的关键问题.
- 建议是基于系统的文献审查,使用预定义的共识建设方法.
- 用证据分级和推系统的强度来制定指南.
主要成果:
- PMRT适用于大多数节点阳性乳腺癌患者的乳腺切除术后和选择节点阴性病例.
- 在局部晚期疾病或残留结节疾病的新辅助疗法后推使用PMRT.
- 指导方针规定了PMRT的治疗量,中度低分离,基于CT的规划和喘息技术.
结论:
- 这些更新的,基于证据的建议旨在标准化和优化PMRT在乳腺癌管理中的临床应用.
- 这些指南涉及PMRT的关键方面,从患者选择到技术交付,提高治疗效率和安全性.
相关概念视频
Cancer Survival Analysis
624
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
624
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Standards of Care II
999
Nurses bear specific legal responsibilities under several federal statutes, including:
999


